Endometrial Cancer

Discussions at a Community Case Forum event emphasized the importance of listening to patient concerns and a multidisciplinary approach when treating advanced endometrial cancer.

Trial data support potential treatment options with durvalumab-based regimens for advanced or recurrent endometrial cancer.

Patients across endometrial cancer subgroups derived a favorable survival benefit with pembrolizumab plus chemotherapy in the KEYNOTE-868 trial.

Patients with microsatellite instability high primary advanced or recurrent endometrial cancer derived a significant survival benefit when treated with dostarlimab plus chemotherapy.

Amanda Duck, PA-C, RD, held a discussion during a Community Case Forum on the progress made in using immunotherapy to treat patients with advanced endometrial cancer and the creativity sometimes needed to address adverse events.

Many symptoms related to endometrial cancer may improve within 1 year in women with endometrial cancer, with the exception of those with high-risk disease.

During a Community Case Forum, Tiffany Bostwick, P.A., discussed how immunotherapy for advanced endometrial cancer has contributed to improved results compared with the previous standard of care.

A priority review has been granted by the FDA to trastuzumab deruxtecan for the treatment of unresectable or metastatic HER2-positive advanced solid tumors.

Those receiving dostarlimab experienced numerical improvements from baseline in terms of quality of life, emotional functioning, pain, and back and pelvis pain scores.

The median progression-free survival was not reached with atezolizumab plus chemotherapy vs 6.9 months in the placebo group of patients with advanced or recurrent endometrial cancer.

Durvalumab plus first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib, emerges as a potentially effective combination for patients with limited treatment options.

The FDA has approved dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, as determined by an FDA-approved test, or microsatellite instability-high.

Patients with TP53 wild-type endometrial cancer experienced a median progression-free survival of 27.4 months vs 5.2 months with placebo.

An analysis of patient-reported outcomes in the phase 3 RUBY trial supports dostarlimab use in patients with primary advanced or recurrent endometrial cancer.

The United Kingdom’s National Institute for Health and Care Excellence has updated their guidelines to recommend pembrolizumab plus lenvatinib for patients with previously treated endometrial cancer.

Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.

Dostarlimab met its primary end point in the phase 3 RUBY trial by increasing the 2-year progression-free survival rate to 36.1%, compared with 18.1% with placebo.

Oncology nurse experts review their experiences with newcomers for the treatment of advanced endometrial cancer and exchange best practices in caring for this population.

In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer.

Courtney R. Arn, APRN-CNP, discusses the recent approval of dostarlimab for patients with mismatch repair–deficient recurrent or advanced endometrial cancer.

Updated findings from the KEYNOTE-146 trial support the use of lenvatinib/pembrolizumab in advanced endometrial cancer.

Dostarlimab-gxly has been granted regular approval for the treatment of patients with dMMR endometrial cancer. The label comes with warnings for immune-mediated adverse effects.

Kathleen Lutz, RN, NP-BC WH, explains the most commonly used first-line treatment options in patients with advanced endometrial cancer who are unsuitable candidates for surgery.

The panel reviews the current treatment modalities for endometrial cancer and in what circumstances each is considered for a patient.

Lenvatinib is approved in combination with pembrolizumab for the treatment of patients with advanced endometrial cancer who have disease progression after systemic therapy, are not candidates for curative surgery or radiation, and who are mismatch repair proficient or not microsatellite instability–high.

Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, met a predetermined progression-free survival end point in the phase 3 RUBY trial.

The panel shares how they determine a treatment regimen for patients with advanced endometrial cancer taking into consideration fertility and family planning, hereditary conditions, and comorbidities.

Kathleen Lutz, RN, NP-BC WH, presents a 76-year-old woman with advanced endometrial cancer, and the panel assesses the chosen treatment regimens.

Certified Nurse Practitioner Kimberly Spickes shares the educational and supportive resources she recommends for patients with newly-diagnosed advanced endometrial cancer.